The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Response to the first-line FOLFOX plus bevacizumab (BEV) therapy to predict responses to the subsequent therapies and survival in the BEV beyond progression (BBP) strategy for metastatic colorectal cancer: A retrospective analysis of CCOG-0801 study.
Goro Nakayama
No relevant relationships to disclose
Keisuke Uehara
No relevant relationships to disclose
Naomi Hayashi
No relevant relationships to disclose
Chie Tanaka
No relevant relationships to disclose
Daisuke Kobayashi
No relevant relationships to disclose
Mitsuro Kanda
No relevant relationships to disclose
Suguru Yamada
No relevant relationships to disclose
Tsutomu Fujii
No relevant relationships to disclose
Hiroyuki Sugimoto
No relevant relationships to disclose
Masahiko Koike
No relevant relationships to disclose
Shuji Nomoto
No relevant relationships to disclose
Michitaka Fujiwara
No relevant relationships to disclose
Yuichi Ando
No relevant relationships to disclose
Yasuhiro Kodera
No relevant relationships to disclose